Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising results ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...